7th ICHNO Abstract book

page 12 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ 7th ICHNO

of SMARCB1 (INI1) (7) is currently retained under the umbrella of SNUC as it is still not clear whether it represents a distinct entity. Using next-generation sequencing, IDH2 mutations at R172 were recently identified in 30% to 50% of SNUCs (8, 9). Further studies have shown that IDH2 mutations can also be found in poorly-differentiated sinonasal carcinomas other than SNUC and that they frequently co-exist with MYC amplifications (9). Notably, the identification of IDH mutations in poorly differentiated sinonasal carcinomas and SNUC has also significant therapeutic implications, as mutant IDH inhibitors have shown promise in the treatment of other malignancies. In conclusion, SNUC remains a poorly understood sinonasal malignancy, but in the next future molecular studies are likely to provide new perspectives for its diagnosis and treatment. References 1) Frierson HF Jr, et al. Am J Surg Pathol. 1986;10:771-9. 2) Mills SE. Endocr Pathol. 1996;7:329-343. 3) Jeng YM, et al. Am J Surg Pathol. 2002;26:371-6. 4) Franchi A, et al. Am J Surg Pathol. 2002;26:1597-604. 5) Lewis JS Jr, et al. (2017) In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds) WHO classification of head and neck tumours. IARC, Lyon, pp 18-20. 6) Stathis A, et al. Cancer Discov. 2016;6:492-500. 7) Agaimy A, et al. Am J Surg Pathol 2017;41:458-471. 8) Jo VY, et al. Mod Pathol 2017;30:650-659 9)Dogan S, et al. J Pathol. 2017;242:400-408.

SP-015 Current status of immunotherapy in Head and Neck cancer L. Licitra Italy

Abstract not received

SP-016 Integration

of

immunotherapy

with

radiotherapy in Head and Neck cancer P. Huber Germany

Abstract not received

Keynote lecture: Keynote lecture 4: SNUC: a sustainable concept?

SP-017 SNUC: a sustainable concept? A. Franchi 1 1 University of Pisa, Department of Translational Research, Pisa, Italy Abstract text Sinonasal undifferentiated carcinoma (SNUC) was first described as a distinct entity by Frierson and coworkers in 1986 (1), as a highly aggressive carcinoma devoid of glandular and squamous differentiation, and histologically consisting of nests, trabeculae, and sheets of medium- sized cells with small to moderate amounts of eosinophilic cytoplasm. A high mitotic rate, tumor necrosis, and prominent vascular permeation were characteristic. Although it was initially thought to represent a large cell variant of neuroendocrine carcinoma, it is now considered a separate entity from the group of sinonasal neuroendocrine tumors (2). More importantly, it was stressed that SNUC has to be separated from nasopharyngeal-type undifferentiated carcinoma and olfactory neuroblastoma, for their better prognosis and response to treatment (3, 4). Still in the recent 4th edition of the WHO classification of head and neck tumors (5), from the histopathologic point of view SNUC remains a diagnosis of exclusion, requiring separation from several other epithelial and non-epithelial high-grade sinonasal malignancies. However, due to the lack of specific criteria, it is likely that the diagnosis of SNUC may have been applied to a heterogeneous group of carcinomas, thus possibly representing a final common pathway of dedifferentiation for a variety of sinonasal epithelial neoplasms. More recently, the refinement in diagnostic criteria and the availability of new molecular markers has led to the separation of specific tumor types from this group of tumors. The first one has been NUT carcinoma, which is a poorly differentiated carcinoma often showing squamous differentiation and presenting a rearrangement of the nuclear protein in testis ( NUTM1 ) gene on chromosome 15q14. In most cases, the partner gene of the fusion is BRD4 (bromodomain-containing protein 4) on 19p13.1, and less frequently BRD3 or WHSC1L1 . NUT carcinoma is a highly aggressive tumor with a median survival <1 year, but the evidence of clinical response to targeted treatments with bromodomain inhibitors underscores the importance of its distinction from other poorly differentiated carcinomas of the sinonasal tract (6). The recently described subset of undifferentiated carcinomas with rhabdoid histologic features and loss

Keynote lecture: Keynote lecture 5: Pushing the limits in Head and Neck robotic surgery

SP-018 Pushing the limits in Head and Neck robotic surgery C. Simon Switzerland

Abstract not received

Proffered papers: Proffered papers 2

OC-019 What is the optimal cut-off of depth of invasion for elective neck dissection in oral cavity cancer? Abstract withdrawn OC-020 Sentinel lymph node biopsy for early stage oral cancer; experience of 3 Dutch Head and Neck centers I. Den Toom 1,2 , K. Boeve 3,4 , R. Van Es 1 , B. De Keizer 5 , S. Van Weert 2 , S. Willems 6 , M. Witjes 3 , E. Bloemena 7,8 , R. Leemans 2 , R. De Bree 1 1 UMC Utrecht, Head and Neck Surgical Oncology, Utrecht, The Netherlands; 2 Amsterdam UMC, Otolaryngology-Head and Neck Surgery, Amsterdam, The Netherlands ; 3 University Medical Center Groningen, Oral and Maxillofacial Surgery, Groningen, The Netherlands ; 4 University Medical Center Groningen, Pathology and Medical Biology, Groningen, The Netherlands ; 5 UMC Utrecht, Radiology and Nuclear Medicine, Utrecht, The Netherlands ; 6 UMC Utrecht, Pathology, Utrecht, The Netherlands ; 7 Amsterdam UMC/Academic Centre for Dentistry ACTA, Oral and Maxillofacial Surgery / Oral Pathology, Amsterdam, The Netherlands ; 8 Amsterdam UMC, Pathology, Amsterdam, The Netherlands